Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186


Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.

Berge EO, Huun J, Lillehaug JR, Lønning PE, Knappskog S.

Biochim Biophys Acta. 2013 Mar;1830(3):2790-7.


Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.

Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE.

Breast Cancer Res. 2012 Mar 15;14(2):R47.


CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE.

PLoS One. 2008 Aug 26;3(8):e3062. doi: 10.1371/journal.pone.0003062.


Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.

Bouchalova P, Nenutil R, Muller P, Hrstka R, Appleyard MV, Murray K, Jordan LB, Purdie CA, Quinlan P, Thompson AM, Vojtesek B, Coates PJ.

J Pathol. 2014 Jul;233(3):238-46. doi: 10.1002/path.4356. Epub 2014 May 21.


Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Børresen-Dale AL.

Cancer Res. 2001 Mar 15;61(6):2505-12.


WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.

Cuddihy AR, Jalali F, Coackley C, Bristow RG.

Mol Cancer Ther. 2008 Apr;7(4):980-92. doi: 10.1158/1535-7163.MCT-07-0471.


p53 in breast cancer subtypes and new insights into response to chemotherapy.

Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, Turpin E, Plassa LF, de Roquancourt A, Bourstyn E, de Cremoux P, Janin A, Giacchetti S, Espié M, de Thé H.

Breast. 2013 Aug;22 Suppl 2:S27-9. doi: 10.1016/j.breast.2013.07.005. Review.


Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.

Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE.

Mol Oncol. 2015 Oct;9(8):1553-64. doi: 10.1016/j.molonc.2015.04.008. Epub 2015 May 8.


Chemosensitivity and p53; new tricks by an old dog.

Lønning PE, Knappskog S.

Breast Cancer Res. 2012 Nov 6;14(6):325. doi: 10.1186/bcr3326.


Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines.

Fernández-Cuesta L, Anaganti S, Hainaut P, Olivier M.

Breast Cancer Res Treat. 2011 Jan;125(1):35-42. doi: 10.1007/s10549-010-0819-x. Epub 2010 Mar 11.


Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.

Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG.

Cancer Res. 2000 Apr 15;60(8):2155-62.


TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.

Geisler S, Børresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, Anker G, Lønning PE.

Clin Cancer Res. 2003 Nov 15;9(15):5582-8.


Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer.

Dalmases A, González I, Menendez S, Arpí O, Corominas JM, Servitja S, Tusquets I, Chamizo C, Rincón R, Espinosa L, Bigas A, Eroles P, Furriol J, Lluch A, Rovira A, Albanell J, Rojo F.

Oncotarget. 2014 Jan 15;5(1):196-210.


p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.

Jackson JG, Pant V, Li Q, Chang LL, Quintás-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, El-Naggar AK, Lozano G.

Cancer Cell. 2012 Jun 12;21(6):793-806. doi: 10.1016/j.ccr.2012.04.027.


P53 and its molecular basis to chemoresistance in breast cancer.

Knappskog S, Lønning PE.

Expert Opin Ther Targets. 2012 Mar;16 Suppl 1:S23-30. doi: 10.1517/14728222.2011.640322. Epub 2012 Feb 8. Review.


A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.

Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Børresen-Dale AL, Overgaard J.

Acta Oncol. 2008;47(4):600-7. doi: 10.1080/02841860802047411.


Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers.

Ooe A, Kato K, Noguchi S.

Breast Cancer Res Treat. 2007 Mar;101(3):305-15. Epub 2006 Jul 5.


Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.

Yndestad S, Austreid E, Svanberg IR, Knappskog S, Lønning PE, Eikesdal HP.

Oncotarget. 2017 Jun 20;8(25):41227-41241. doi: 10.18632/oncotarget.17167.


P53-miR-191-SOX4 regulatory loop affects apoptosis in breast cancer.

Sharma S, Nagpal N, Ghosh PC, Kulshreshtha R.

RNA. 2017 Aug;23(8):1237-1246. doi: 10.1261/rna.060657.117. Epub 2017 Apr 27.


Supplemental Content

Support Center